Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Haber

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
Oncotarget|April 11, 2015
MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastomaDiana T Lau, Claudia L Flemming, Samuele Gherardi, et al.
Journal of Personalized Medicine|November 26, 2025
Data Sharing, Biopsies and Patient Confidentiality in a Precision Medicine Trial for Childhood Cancer: A Mixed Method Study of Parents, Oncologists, and Scientists' PerspectivesYvanna Lei, Kate Hetherington, Rebecca Daly, et al.
Expert Opinion on Drug Discovery|November 22, 2021
Methodological advances in the discovery of novel neuroblastoma therapeuticsMiguel F Segura, Aroa Soriano, Josep Roma, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesisTao Liu, Andrew E L Tee, Antonio Porro, et al.
Biochemical Pharmacology|December 22, 2019
CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growthTony Huynh, Jayne Murray, Claudia L Flemming, et al.
Molecular Oncology|March 22, 2016
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesisDaniel R Carter, Selina K Sutton, Marina Pajic, et al.
Frontiers in Oncology|February 7, 2022
Systematic <i>In Vitro</i> Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged LeukemiaMawar Karsa, Emma Ronca, Angelika Bongers, et al.
Leukemia|January 10, 2019
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesisJennifer R Lynch, Basit Salik, Patrick Connerty, et al.
The Journal of Biological Chemistry|April 26, 2006
The estrogen-responsive B box protein is a novel regulator of the retinoid signalBelamy B Cheung, Jessica Bell, Anna Raif, et al.
Cancer Research|December 8, 2016
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated CancersMoonSun Jung, Amanda J Russell, Bing Liu, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Oncotarget|April 11, 2015
MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastomaDiana T Lau, Claudia L Flemming, Samuele Gherardi, et al.
Journal of Personalized Medicine|November 26, 2025
Data Sharing, Biopsies and Patient Confidentiality in a Precision Medicine Trial for Childhood Cancer: A Mixed Method Study of Parents, Oncologists, and Scientists' PerspectivesYvanna Lei, Kate Hetherington, Rebecca Daly, et al.
Expert Opinion on Drug Discovery|November 22, 2021
Methodological advances in the discovery of novel neuroblastoma therapeuticsMiguel F Segura, Aroa Soriano, Josep Roma, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesisTao Liu, Andrew E L Tee, Antonio Porro, et al.
Biochemical Pharmacology|December 22, 2019
CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growthTony Huynh, Jayne Murray, Claudia L Flemming, et al.
Molecular Oncology|March 22, 2016
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesisDaniel R Carter, Selina K Sutton, Marina Pajic, et al.
Frontiers in Oncology|February 7, 2022
Systematic <i>In Vitro</i> Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged LeukemiaMawar Karsa, Emma Ronca, Angelika Bongers, et al.
Leukemia|January 10, 2019
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesisJennifer R Lynch, Basit Salik, Patrick Connerty, et al.
The Journal of Biological Chemistry|April 26, 2006
The estrogen-responsive B box protein is a novel regulator of the retinoid signalBelamy B Cheung, Jessica Bell, Anna Raif, et al.
Cancer Research|December 8, 2016
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated CancersMoonSun Jung, Amanda J Russell, Bing Liu, et al.
Pageof 19